Stock Events

Stock Events

INmune Bio 

$1.6200
53
+$0.01+0.62%Friday 06:08

Statistics

Day High
1.62
Day Low
1.62
52W High
2.02
52W Low
1.21
Volume
1
Avg. Volume
-
Mkt Cap
44.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q3 2025
Q1 2026
Q2 2026
Next
-0.32
-0.23
-0.14
-0.05
Expected EPS
-0.146667
Actual EPS
N/A

Financials

-91,866%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
50,000Revenue
-45.93MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INMB.BOATS. It's not an investment recommendation.
Microsoft
5
MSFT
Tesla
5
TSLA
NVIDIA
5
NVDA
Horizon Technology Finance
5
HRZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.49B
Biogen focuses on neurodegenerative diseases, directly competing with INMB's Alzheimer's disease treatment research.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, directly competing with INMB's efforts in this area.
Anavex Life Sciences
AVXL
Mkt Cap168.71M
Anavex Life Sciences Corp. focuses on developing novel therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, similar to INMB.
AC Immune SA
ACIU
Mkt Cap270.94M
AC Immune SA specializes in neurodegenerative diseases, including Alzheimer's, directly competing with INMB's research focus.
Arbutus Biopharma
ABUS
Mkt Cap881.57M
Arbutus Biopharma Corporation works on immune modulator therapies, which could overlap with INMB's work on the immune system in neurodegenerative diseases.
Incyte
INCY
Mkt Cap23.37B
Incyte Corporation has a broad portfolio that includes treatments for cancer and autoimmune diseases, competing with INMB's work on the immune system's role in disease.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals is pioneering RNAi therapeutics, which could compete with INMB's approach to treating neurological diseases at the genetic level.

About

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Show More
CEO
ISIN
US45782T1051

Listings

BOATS
BOATS
INMB.BOATS
XNAS
US
INMB

0 Comments

Share your thoughts

FAQs

What is INmune Bio stock price today?▼
The current price of INMB.BOATS is $1.62 USD — it has increased by +0.62% in the past 24 hours. Watch INmune Bio stock price performance more closely on the chart.
What is INmune Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange INmune Bio stocks are traded under the ticker INMB.BOATS.
What is INmune Bio market cap?▼
Today INmune Bio has the market capitalization of 44.96M
When is the next INmune Bio earnings date?▼
INmune Bio is going to release the next earnings report on November 5, 2026.
What were INmune Bio earnings last quarter?▼
INMB.BOATS earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.21 USD resulting in a +75.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is INmune Bio revenue for the last year?▼
INmune Bio revenue for the last year amounts to 50,000 USD.
What is INmune Bio net income for the last year?▼
INMB.BOATS net income for the last year is -45.93M USD.
In which sector is INmune Bio located?▼
INmune Bio operates in the Other sector.
When did INmune Bio complete a stock split?▼
INmune Bio has not had any recent stock splits.